{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:18:55Z","timestamp":1787624335515,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05503-6","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:13:45Z","timestamp":1780114425000},"page":"17839-17856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PIM1-mediated signalling as a therapeutic target in breast cancer: repurposing venetoclax for targeted inhibition"],"prefix":"10.1007","volume":"399","author":[{"given":"Sailayee","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirukumaran","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha Sankar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"5503_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-023-01721-1","volume":"22","author":"M Bellon","year":"2023","unstructured":"Bellon M, Nicot C (2023) Targeting Pim kinases in hematological cancers: molecular and clinical review. Mol Cancer 22(1):18. https:\/\/doi.org\/10.1186\/s12943-023-01721-1","journal-title":"Mol Cancer"},{"issue":"1","key":"5503_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13557-z","volume":"7","author":"J Bogusz","year":"2017","unstructured":"Bogusz J, Zrubek K, Rembacz KP et al (2017) Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Sci Rep 7(1):13399. https:\/\/doi.org\/10.1038\/s41598-017-13557-z","journal-title":"Sci Rep"},{"issue":"11","key":"5503_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/nm.4198","volume":"22","author":"F Bras\u00f3-Maristany","year":"2016","unstructured":"Bras\u00f3-Maristany F, Filosto S, Catchpole S et al (2016) PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med 22(11):1303\u20131313. https:\/\/doi.org\/10.1038\/nm.4198","journal-title":"Nat Med"},{"key":"5503_CR4","doi-asserted-by":"publisher","first-page":"1291920","DOI":"10.3389\/fphar.2023.1291920","volume":"14","author":"Q Cao","year":"2023","unstructured":"Cao Q, Wu X, Zhang Q, Gong J, Chen Y, You Y, Shen J, Qiang Y, Cao G (2023) Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Front Pharmacol 14:1291920. https:\/\/doi.org\/10.3389\/fphar.2023.1291920","journal-title":"Front Pharmacol"},{"issue":"6","key":"5503_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41388-023-02914-0","volume":"43","author":"SS Chauhan","year":"2024","unstructured":"Chauhan SS, Casillas AL, Vizzerra AD et al (2024) PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer. Oncogene 43(6):406\u2013419. https:\/\/doi.org\/10.1038\/s41388-023-02914-0","journal-title":"Oncogene"},{"key":"5503_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116016","volume":"264","author":"S Chen","year":"2024","unstructured":"Chen S, Yang Y, Yuan Y, Liu B (2024) Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors. Eur J Med Chem 264:116016. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116016","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5503_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01898-y","volume":"22","author":"R Choudhury","year":"2024","unstructured":"Choudhury R, Bahadi CK, Ray IP et al (2024) PIM1 kinase and its diverse substrate in solid tumors. Cell Commun Signal 22(1):529. https:\/\/doi.org\/10.1186\/s12964-024-01898-y","journal-title":"Cell Commun Signal"},{"issue":"11","key":"5503_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","volume":"118","author":"J Cortes","year":"2018","unstructured":"Cortes J, Tamura K, DeAngelo DJ et al (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118(11):1425\u20131433. https:\/\/doi.org\/10.1038\/s41416-018-0082-1","journal-title":"Br J Cancer"},{"issue":"5","key":"5503_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-019-00966-3","volume":"26","author":"X Gao","year":"2019","unstructured":"Gao X, Liu X, Lu Y et al (2019) PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-Myc activation. Breast Cancer 26(5):663\u2013671. https:\/\/doi.org\/10.1007\/s12282-019-00966-3","journal-title":"Breast Cancer"},{"issue":"5","key":"5503_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/iub.70020","volume":"77","author":"T Kandasamy","year":"2025","unstructured":"Kandasamy T, Sarkar S, Zochedh A, Kathiresan T, Ghosh SS (2025) Synergistic effects of Epirubicin\u2010Vorinostat\u2010Pimozide drug cocktail on proliferation, stemness, invasiveness, and fatty acid metabolism in breast cancer cells. IUBMB Life 77(5):e70020. https:\/\/doi.org\/10.1002\/iub.70020","journal-title":"IUBMB Life"},{"issue":"8","key":"5503_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202100300","volume":"41","author":"T Kandasamy","year":"2022","unstructured":"Kandasamy T, Sen P, Ghosh SS (2022) Multi\u2010targeted drug repurposing approach for breast cancer via integrated functional network analysis. Mol Inform 41(8):2100300. https:\/\/doi.org\/10.1002\/minf.202100300","journal-title":"Mol Inform"},{"issue":"6","key":"5503_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","volume":"123","author":"EK Keeton","year":"2014","unstructured":"Keeton EK, McEachern K, Dillman KS et al (2014) AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123(6):905\u2013913. https:\/\/doi.org\/10.1182\/blood-2013-04-495366","journal-title":"Blood"},{"issue":"11","key":"5503_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB et al (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3(11):935\u201349. https:\/\/doi.org\/10.1038\/nrd1549","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5503_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.mce.2012.10.028","volume":"365","author":"M Malinen","year":"2013","unstructured":"Malinen M, J\u00e4\u00e4skel\u00e4inen T, Pelkonen M, Heikkinen S, V\u00e4is\u00e4nen S, Kosma VM, Nieminen K, Mannermaa A, Palvimo JJ (2013) Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breasttumors. Mol Cell Endocrinol 365(2):270\u2013276. https:\/\/doi.org\/10.1016\/j.mce.2012.10.028","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"5503_CR15","first-page":"1","volume":"3","author":"W Mo","year":"2012","unstructured":"Mo W, Zhang J-T (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3(1):1\u201327","journal-title":"Int J Biochem Mol Biol"},{"issue":"16","key":"5503_CR16","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"issue":"4","key":"5503_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bcp.2012.12.006","volume":"85","author":"K Natarajan","year":"2013","unstructured":"Natarajan K, Bhullar J, Shukla S et al (2013) The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol 85(4):514\u2013524. https:\/\/doi.org\/10.1016\/j.bcp.2012.12.006","journal-title":"Biochem Pharmacol"},{"key":"5503_CR18","doi-asserted-by":"publisher","unstructured":"Oliviero, Salvatore, Alessio Zippo, Alessandra De Robertis, and Riccardo Serafini. 2007. \u201cPIM1-Dependent Phosphorylation of Histone H3 at Serine 10 Is Required for MYC-Dependent Transcriptional Activation and Oncogenic Transformation.\u201d Nature Precedings, ahead of print, June 20. https:\/\/doi.org\/10.1038\/npre.2007.100.1.","DOI":"10.1038\/npre.2007.100.1"},{"issue":"2","key":"5503_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mc.23848","volume":"64","author":"S Sarkar","year":"2025","unstructured":"Sarkar S, Kandasamy T, Ghosh SS (2025) Imatinib impedes EMT and Notch signalling by inhibiting P300 acetyltransferase in breast cancer cells. Mol Carcinog 64(2):344\u2013356. https:\/\/doi.org\/10.1002\/mc.23848","journal-title":"Mol Carcinog"},{"key":"5503_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110529","volume":"102","author":"P Sen","year":"2023","unstructured":"Sen P et al (2023) Multi-targeting TACE\/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide. Cell Signal 102:110529. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110529","journal-title":"Cell Signal"},{"issue":"2","key":"5503_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020466","volume":"12","author":"J-Q Wang","year":"2020","unstructured":"Wang J-Q, Li JY, Teng Q-X et al (2020) Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells. Cancers 12(2):466. https:\/\/doi.org\/10.3390\/cancers12020466","journal-title":"Cancers"},{"issue":"1","key":"5503_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14392-z","volume":"11","author":"KC Wood","year":"2020","unstructured":"Wood KC (2020) Overcoming MCL-1-driven adaptive resistance to targeted therapies. Nat Commun 11(1):531. https:\/\/doi.org\/10.1038\/s41467-020-14392-z","journal-title":"Nat Commun"},{"issue":"2","key":"5503_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/mol.109.061713","volume":"78","author":"Y Xie","year":"2010","unstructured":"Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR (2010) Pim-1 kinase protects P-Glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol 78(2):310\u2013318. https:\/\/doi.org\/10.1124\/mol.109.061713","journal-title":"Mol Pharmacol"},{"key":"5503_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1443784","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Liu C, Lei Y, Liu Z, Zhu B, Zhao D (2024) PIM1 signaling in immunoinflammatory diseases: An emerging therapeutic target. Front Immunol 15:1443784. https:\/\/doi.org\/10.3389\/fimmu.2024.1443784","journal-title":"Front Immunol"},{"issue":"3","key":"5503_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/0008-5472.CAN-07-2545","volume":"68","author":"L Yin","year":"2008","unstructured":"Yin L, Castagnino P, Assoian RK (2008) ABCG2 expression and side population abundance regulated by a transforming growth factor \u03b2\u2013directed epithelial-mesenchymal transition. Cancer Res 68(3):800\u2013807. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2545","journal-title":"Cancer Res"},{"key":"5503_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114346","volume":"237","author":"IF Zattoni","year":"2022","unstructured":"Zattoni IF, Delabio LC, Dutra JDP et al (2022) Targeting Breast Cancer Resistance Protein (BCRP\/ABCG2): functional inhibitors and expression modulators. Eur J Med Chem 237:114346. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114346","journal-title":"Eur J Med Chem"},{"issue":"2","key":"5503_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s13577-021-00656-3","volume":"35","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Aziz AUR, Zhang H, Zhang Z, Li N, Liu B (2022) A systematic review on active sites and functions of PIM-1 protein. Hum Cell 35(2):427\u2013440. https:\/\/doi.org\/10.1007\/s13577-021-00656-3","journal-title":"Hum Cell"},{"issue":"9","key":"5503_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07039-0","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Wang X, Li Z et al (2024a) PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3\u03b2 signaling pathway in EGFR-mutant non-small cell lung cancer. Cell Death Dis 15(9):644. https:\/\/doi.org\/10.1038\/s41419-024-07039-0","journal-title":"Cell Death Dis"},{"issue":"9","key":"5503_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07039-0","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Wang X, Li Z et al (2024b) PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3\u03b2 signaling pathway in EGFR-mutant non-small cell lung cancer. Cell Death Dis 15(9):644. https:\/\/doi.org\/10.1038\/s41419-024-07039-0","journal-title":"Cell Death Dis"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05503-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:23:54Z","timestamp":1787621034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5503"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05503-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}